Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Rockefeller University has given license for its latest Lysin enzyme (referred to as CF-301), that dissolve and kill tens of millions of bacteria in seconds, to ContraFect.
Subscribe to our email newsletter
CF-301, produced by fermentation at concentrations exceeding 5g/l, is soluble, stable and potent.
The Lysins possess a therapeutic window that occurs virtually instantly while the Monoclonal Antibodies remain in the blood stream for weeks and provide long-term benefit.
ContraFect chairman and CEO Robert Nowinski said with the addition of this latest Lysin, their second against Staphylococcus, ContraFect has added depth to its clinical program and pipeline.
ContraFect Business Development VP Barry Kappel said CF-301 moves directly to the front of their pipeline and they anticipate having an IND-submission to the FDA for this product in Q2 2012.
"Its potent activity against all forms of Staph infections, including methicillin-resistant (MRSA) and vancomycin-resistant strains (VISA/VRSA), makes this molecule of extreme importance, not only to ContraFect, but world-wide as well," Kappel said.